Codexis, Inc. $CDXS Shares Bought by Prescott Group Capital Management L.L.C.

Prescott Group Capital Management L.L.C. lifted its stake in shares of Codexis, Inc. (NASDAQ:CDXS) by 23.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 700,591 shares of the biotechnology company’s stock after purchasing an additional 131,617 shares during the quarter. Prescott Group Capital Management L.L.C.’s holdings in Codexis were worth $1,709,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in CDXS. Integrity Alliance LLC. purchased a new position in Codexis during the first quarter worth approximately $30,000. US Bancorp DE grew its holdings in Codexis by 11,125.0% in the 1st quarter. US Bancorp DE now owns 17,960 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 17,800 shares in the last quarter. Elmwood Wealth Management Inc. acquired a new stake in shares of Codexis in the 2nd quarter worth $53,000. Invesco Ltd. raised its holdings in shares of Codexis by 100.0% during the 1st quarter. Invesco Ltd. now owns 67,447 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 33,716 shares during the period. Finally, Clough Capital Partners L P raised its holdings in shares of Codexis by 93.8% during the 1st quarter. Clough Capital Partners L P now owns 69,000 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 33,400 shares during the period. 78.54% of the stock is currently owned by hedge funds and other institutional investors.

Codexis Stock Down 17.2%

Shares of NASDAQ:CDXS opened at $1.69 on Friday. The company has a market capitalization of $152.55 million, a price-to-earnings ratio of -2.04 and a beta of 2.57. Codexis, Inc. has a 12-month low of $1.61 and a 12-month high of $6.08. The business has a 50-day moving average price of $2.48 and a 200 day moving average price of $2.56. The company has a current ratio of 5.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.71.

Codexis (NASDAQ:CDXS) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07). Codexis had a negative net margin of 113.67% and a negative return on equity of 105.83%. The company had revenue of $8.60 million during the quarter, compared to analyst estimates of $18.52 million. Sell-side analysts expect that Codexis, Inc. will post -0.77 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Codexis in a research report on Wednesday, October 8th. Wall Street Zen cut shares of Codexis from a “hold” rating to a “strong sell” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $11.00.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.